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Abstract: Akkermansia muciniphila is a mucin-degrading bacterium of the phylum Verrucomicrobia.
Its abundance in the human intestinal tract is inversely correlated to several disease states.
A. muciniphila resides in the mucus layer of the large intestine, where it is involved in maintaining
intestinal integrity. We explore the presence of Akkermansia-like spp. based on its 16S rRNA sequence
and metagenomic signatures in the human body so as to understand its colonization pattern in time
and space. A. muciniphila signatures were detected in colonic samples as early as a few weeks after
birth and likely could be maintained throughout life. The sites where Akkermansia-like sequences
(including Verrucomicrobia phylum and/or Akkermansia spp. sequences found in the literature) were
detected apart from the colon included human milk, the oral cavity, the pancreas, the biliary system,
the small intestine, and the appendix. The function of Akkermansia-like spp. in these sites may differ
from that in the mucosal layer of the colon. A. muciniphila present in the appendix or in human milk
could play a role in the re-colonization of the colon or breast-fed infants, respectively. In conclusion,
even though A. muciniphila is most abundantly present in the colon, the presence of Akkermansia-like
spp. along the digestive tract indicates that this bacterium might have more functions than those
currently known.
Keywords: Akkermansia muciniphila; mucin; gut microbiota; ecological niches; digestive tract; human
breast milk
1. Introduction
The microbial community in the human gut plays a role in the balance between health and disease.
The gastrointestinal (GI) microbiota has recently emerged as an important factor in human physiology,
both under homeostatic and pathological conditions [1]. Characterization of the GI microbiota may
identify gut-related abnormalities and play an important role in establishing functional linkages
to health status [2]. Some GI tract disorders with associated microbiota imbalance include celiac
disease [2], irritable bowel syndrome (IBS) [3,4], inflammatory bowel disease (IBD) [5–7], and type 2
diabetes (T2D) [8–10].
The A. muciniphila-type strain MucT of the phylum Verrucomicrobia was first described in 2004 [11].
This bacterium was isolated from the fecal sample of a healthy individual using purified mucin as
the sole source of carbon, nitrogen, and energy for growth. A. muciniphila has only a few similarities
to other representatives of Verrucomicrobia [12]. Interestingly, Akkermansia is the only genus of the
Verrucomicrobia phylum found in gastrointestinal samples. Large differences were observed between
verrucomicrobial genomes, in terms of the GC content and genome sizes. In contrast, similarities were
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observed within the Verrucomicrobia phylum as a large proportion of the proteins in verrucomicrobial
proteomes were found to contain signal peptides (26.1% for A. muciniphila). In the colon of a healthy
human being, A. muciniphila is present in high levels with an abundance of approximately 3% [6,13].
The core activity of A. muciniphila is to degrade mucus using the many mucolytic enzymes encoded in
its genome [6,12].
The presence of A. muciniphila has been associated with healthy intestine and its abundance
has been inversely correlated to several disease states [6–8,14–16]. For example, in cases of IBD
(patients with ulcerative colitis and Crohn’s disease), the abundance of A. muciniphila was found
to be decreased [6,7]. Also, individuals with acute appendicitis were found to harbor a decreased
amount of A. muciniphila [14]. In this case, the abundance of A. muciniphila was inversely related to the
severity of the appendicitis. Furthermore, obese children were shown to have a significant reduction in
A. muciniphila-like bacteria [15]. In a comprehensive study of infants in daycare, A. muciniphila-based
sequences were found to be reduced in children that had received multiple antibiotic courses and were
at risk for later life obesity [17]. In concordance with these studies, another reported the association of
A. muciniphila with a healthier metabolic status in obese and overweight individuals [16]. Moreover,
the genus Akkermansia and its metabolic pathways were found to be enriched in athletes with a low
body mass index [18,19]. Lastly, the abundance of Verrucomicrobiae was significantly reduced in
pre-diabetes and T2D [8]. It is important to note that these diseases may have an effect on the integrity
or thickness of the mucus layer, and thereby effect the abundance of A. muciniphila. To confirm this,
studies taking both the microbial composition and mucus layer integrity into account should be
performed. Altogether, these studies indicate the correlation of A. muciniphila to a healthy status and
indicate the possible use of Akkermansia spp. as a biomarker for disease.
Interactions between the host and A. muciniphila have been studied in mice [10,20]. Colonization
by A. muciniphila resulted in transcriptional changes, leading to an increase in the expression of genes
associated with immune responses [20]. Furthermore, A. muciniphila was found to strengthen the
gut barrier function in mice [10]. By doing so, A. muciniphila played a role in normalizing metabolic
endotoxemia and adipose tissue metabolism. These findings have been supported by another study
showing that A. muciniphila affects genes involved in cellular lipid metabolism [21]. The effect of a
fiber-free diet was studied in mice colonized with a synthetic community consisting of 14 species,
including A. muciniphila [22]. Feeding these mice a fiber-free diet was found to damage the mucus
barrier. The changes in microbial community included an increased abundance of A. muciniphila
and a switch in metabolism of gut microbiota species from fiber degradation to mucus glycan
degradation [22,23]. An in vitro study using human colonic cell lines (Caco-2 and HT-29) demonstrated
the adherence of A. muciniphila to the intestinal epithelium, thereby strengthening the epithelial
integrity rather than causing a pro-inflammatory reaction [24]. Lastly, outer membrane proteins of
A. muciniphila were found to have a role in the modulation of immune responses [25]. Recently,
one of the outer membrane proteins was identified (Amuc_1100) [26]. This study demonstrated
that the outer membrane pili-like protein is involved in immune regulation and the enhancement of
trans-epithelial resistance.
Several studies have purposely or unintentionally revealed the presence of Akkermansia-like spp.
in segments of the human body other than the colon, where A. muciniphila might also have important
functions. In this review, we will discuss the presence of Verrucomicrobia and Akkermansia-like spp. in
different anatomic regions of the digestive tract. The physiology and environmental parameters of
these anatomic regions will be taken into account to assess the possibility of A. muciniphila to colonize
and be active at these niches.
2. Prevalence of Akkermansia muciniphila through Geography and Age in the Human
Gastrointestinal Tract
Akkermansia muciniphila is present in the intestinal tract throughout different stages of life [27,28].
This was determined using fecal samples from healthy subjects divided into groups based on their age,
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analyzed using fluorescence in situ hybridization (FISH) and quantitative PCR (qPCR). The number of
bacteria related to A. muciniphila significantly increased from early life to adult subjects [27,28]. When
focusing on the prevalence of bacteria related to A. muciniphila, 16% of one-month old infants in this study
were found to harbor Akkermansia in their intestinal tracts [27]. At this very young age, the concentration
of A. muciniphila ranged between 2.05 and 4.36 log cells per gram of feces. Subsequently, at 6 months
of age the percentage of infants where A. muciniphila could be detected increased to 72%, with a further
increase to 90% in 12-month-old infants. The concentrations were in the ranges of 2.50–7.30 and 2.80–9.50
log cells per gram of feces in 6-month-old and 12-month-old infants, respectively. However, in this study
no correlation was made between the A. muciniphila abundance and the feeding mode of the infant (breast
and/or formula feeding). Other studies not primarily focusing on the presence of A. muciniphila have also
shown the presence of Akkermansia-like spp. or the Verrucomicrobia phylum in the infant’s gut at different
geographical locations, such as Finland, Germany, and Malawi [29–31]. The presence of A. muciniphila in
the infant’s gut could be considered as a marker for gut microbiota development and diversity [29]. Next
to infants, adults (25–35 years old) were found to harbor 5–8.8 log cells per gram of feces of A. muciniphila,
while a significant decrease was noted in elderly subjects (80–82 years old) namely, 95.5% [27]. These
outcomes differed in another study, where young adults harbored significantly less Akkermansia spp. than
the elderly both in terms of prevalence and abundance [32]. In addition, centenarians were found to
harbor a higher concentration of Akkermansia spp. Also, semi-supercentenarians (individuals with an age
of 105 or higher) had a higher concentration of Akkermansia-like spp. than other (younger) age groups in
the study [33]. A. muciniphila is proposed to have a role in the immunological and metabolic health of
semi-supercentenarians, rendering it a biomarker for healthy aging. In contrast to age, gender does not
play a role considering the amount of A. muciniphila [28].
The genome of A. muciniphila (ATCC BAA-835) was sequenced and annotated [12]. These
sequences were used to mine 37 reported gastrointestinal tract (GIT) metagenomes derived from adults
belonging to six nationalities to evaluate the presence and genetic diversity of Akkermansia spp. in the
human gut. The prevalence of Akkermansia spp. in these metagenomes was found to be 30%, using a
cutoff of >95% identity to 16S rRNA. When queried with the Akkermansia genome (identity > 90%),
62% of the metagenomic libraries were shown to be Akkermansia carriers, which is comparable to
earlier findings of a Finnish cohort [27]. The relative abundances of Akkermansia spp. DNA in these
libraries varied from <0.01% to almost 4% [12]. However, higher abundances of Verrucomicrobia in
the GIT have also been reported, for example in biopsy samples (up to ~15% depending on the method
and individual) [34]. The analysis of fecal samples from the Metagenomics of the Human Intestinal
Tract (MetaHit) project, derived from Danish and Chinese individuals, revealed country-specific
differences in gut microbiota [35]. In terms of Akkermansia-like spp., the mean relative abundance of
Danish individuals (0.0137) was higher than that of Chinese individuals (0.0015). Moreover, a recent
study showed that Verrucomicrobia sequences were found to be enriched in the guts of industrialized
regions compared to the guts of traditional populations (p < 2 × 10−16), such as the traditional Hadza
hunter-gatherers [36]. However, as with many comparative microbiota analyses, confounding factors
related to sample processing, DNA extraction, and subsequent processing cannot be ruled out [37].
A study performed in China showed that the frequency of A. muciniphila is lower in southern Chinese
than in European populations [38]. The frequency in southern China was found to be 51.71%, which is
significantly lower than the ~75% found in European populations [27,38]. Interestingly, in southern
China the highest frequencies were detected among the elderly, while in European populations a
significant decrease was noted for the elderly. This observed difference may be due to external factors
affecting the microbiota composition, including geographic location, diet, and age.
The human intestine may be colonized by different Akkermansia-like spp. [12]. The 16S rRNA
sequences detected in metagenomic datasets suggested colonization by at least eight different
Akkermansia-like spp. However, as these sequences derived from short Illumina reads, mis-assembly and
other technical biases may have affected this conclusion. Moreover, it is also possible that simultaneous
colonization by different species occurs. Recently, 39 A. muciniphila strains were isolated from human
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and mouse feces and subsequently analyzed for their 16S rRNA sequences and draft genomes [38,39].
All 16S rRNA sequences from these strains shared over 97% sequence identity with that of the type
strain A. muciniphila MucT isolated from Europe, suggesting that they represent isolates from the same
species. Using these isolates, three phylogroups (AmI, AmII, and AmIII) were identified based on
core genome single nucleotide polymorphisms (SNPs). We constructed a maximum likelihood tree
based on the available 16S sequences of the Chinese A. muciniphila strains in the National Center for
Biotechnology Information (NCBI) sequence database and all other 16S rRNA Akkermansia-like sequences
derived from colonic and ileal biopsy samples derived from the SILVA small subunit Reference 132
dataset (Figure 1a and Supplementary Figure S1). In this tree, the newly isolated Chinese A. muciniphila
strains fall into two out of three distinct clades (clades one and two) that, however, have only minimal
differences. In comparison with the type strain, the first clade has 99–100% identity, the second clade
98–99%, and the third clade 98%. Interestingly, the Chinese A. muciniphila strains have reportedly distinct
metabolic and functional features [39]. However, unlike A. muciniphila-type strain MucT, complete
closed genomes of these Chinese A. muciniphila strains have not been reported. Furthermore, functional
analysis of the Chinese A. muciniphila strains has not been performed, but the strains are able to grow on
mucus [39]. Next to A. muciniphila, only one other Akkermansia-like sp. has been validly described, namely
Akkermansia glycaniphila strain PytT isolated from reticulated python feces (included in the phylogenetic
tree shown in Figure 1a) [40,41]. The closest relative of A. glycaniphila is A. muciniphila MucT, sharing
94.4% 16S rRNA sequence similarity [40]. The average nucleotide identity between the A. glycaniphila
PytT genome and the genome of A. muciniphila MucT was found to be 79.7%. Compared to A. muciniphila,
A. glycaniphila is also able to use mucin as a sole carbon, energy, and nitrogen source. However, the
relatedness between these two species, determined by DNA-DNA hybridization, is low, namely 28.3%.
To be able to compare functional differences between Chinese A. muciniphila strains, the Akkermansia-like
sequences found in biopsies of the ileum and large intestine (included in the tree), and A. muciniphila
MucT, enclosed genomes and functional analyses are needed.
Altogether, A. muciniphila’s presence varies among individuals. Its abundance varies not only
from person to person but also from age group to age group. On top of that, other factors such as
geographical location may also play an important role in the presence and richness of Akkermansia-like
spp. in the human GIT.
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Figure 1. (a) Akkermansia is not only present in the large intestine, but also in other anatomic regions
of the digestive tract. A schematic overview of the positioning of 16S rRNA clones in the small
and large intestines and the available sequences of the Chin se A. muciniphila strains towards the
A. muciniphil -type strain MucT and A. glycaniphila PytT. The percentages indicate the compositions of
the clades. The tree was generated using the randomized axelerated maximum likelihood (RAxML)
method version 7.0.3 in ARB using a 40% positional conservatory filter [42]. The original detailed
maximum likelihood tree is shown in Supplementary Figure S1. Similar groups were observed using
the neighbor joining method (Supplementary Figure S2). (b) Overview of Verrucomicrobia/Akkermansia
sequences in the human digestive tract.
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3. Physiologic Adaptation of Akkermansia muciniphila to the Human GIT
A. muciniphila is an oval shaped, anaerobic Gram-negative bacterium that was first described by
Derrien et al. [11]. Transmission electron microscopy revealed the presence of filamentous structures
on MucT cells when grown on mucin medium. On top of this, strain MucT is able to exclude Indian
ink, suggesting that the filamentous structures are capsular polymers. More recently, outer membrane
proteins of A. muciniphila were analyzed, which resulted in the identification of pili proteins [13,25,26].
When focusing on the growth parameters of A. muciniphila, it is known that growth was
observed between temperatures of 20 and 40 ◦C and pH values of 5.5–8.0 (Figure 2) [11]. However,
the optimum growth temperature and pH are 37 ◦C and 6.5, respectively. A. muciniphila is an obligate
chemoorganotroph, utilizing mucus as a sole carbon, nitrogen, and energy source [11]. Consequently,
the short chain fatty acids (SCFAs) acetate, propionate, and to smaller extent 1,2-propanediol and
succinate are produced [11,43]. Another factor that influences the growth of A. muciniphila is the
presence of oxygen. A. muciniphila was found to be able to tolerate and even benefit from nanomolar
concentrations of oxygen in liquid medium [44]. Upon the presence of oxygen, there is a change of
acetate to propionate production by A. muciniphila. This results in an increased production of ATP and
NADH, which enhances the growth of A. muciniphila.
To compose a minimal medium for A. muciniphila, a genome-scale metabolic model was
constructed [43]. This model predicts the degradation of mucin-derived monosaccharides. The model
showed that A. muciniphila is able to synthesize all essential amino acids, except for L-threonine, was
not present in the pathway. Furthermore, growth experiments revealed that A. muciniphila can degrade
a variety of sugars such as glucose, N-Acetylglucosamine (GlcNAc), N-Acetylgalactosamine (GalNAc),
and fucose. However, to obtain growth large amounts of casein tryptone, mucin or a rich medium was
required. Hereafter, another study showed that A. muciniphila does not code for GlmS, which mediates
the conversion of fructose-6-phosphate to glucosamine-6-phosphate [45]. This reaction is essential for
peptidoglycan formation. Therefore, the degradation of glucose does not lead to biomass production.
A. muciniphila does code for NagB, which catalyzes the reverse reaction, indicating that the addition of
GlcNAc is essential for growth of A. muciniphila. Altogether, this information led to the development
of a defined minimal medium for A. muciniphila, in which L-threonine and GlcNAc or GalNAc are
essential components for growth [45].
Recently, the growth of A. muciniphila in the presence of bile has been studied [46]. Interestingly,
the A. muciniphila abundance was positively correlated to circulating primary bile acids in mice [47].
The addition of 0.1%, 0.5%, and 1% porcine bile extract resulted in increased growth of A. muciniphila
in comparison to the medium that did not contain bile [46]. In contrast, purified bile salts addition of
0.5% or higher resulted in inhibited growth of A. muciniphila, whereas the addition of 0.1% purified
bile salts did not inhibit growth [48]. Moreover, the survival of A. muciniphila in gastric juice was found
to be very low [46].
Several studies have described the antibiotic resistance of A. muciniphila [49,50]. The type
strain of A. muciniphila (MucT) was found to be susceptible to imipenem, piperacillin/tazobactam,
and doxycycline, while resistance was noted for vancomycin, metronidazole, and penicillin G [49].
Another A. muciniphila strain was resistant against vancomycin and ofloxacin, but susceptible
to penicillin, amoxicillin, ceftriaxone, and imipenem [50]. A. muciniphila MucT has potential
beta-lactamase genes and may code for a 5-nitroimidazole antibiotic resistance protein [12]. The
in silico prediction of a strain directly sequenced from stool (A. muciniphila strain Urmite) predicted the
presence of antibiotic resistance genes for the classes beta-lactamases, glycopeptides, MLS (macrolides,
lincosamides, streptogramines), phenicol, sulphonamide, tetracycline, and trimethoprim [51]. Guo
et al. described the presence of three antibiotic resistance genes in A. muciniphila strain GP36, which
originated from plasmid pRSF1010 (8684 bp) of Salmonella enterica [39]. This indicates that A. muciniphila
might acquire antibiotic resistance genes through lateral gene transfer.




Figure  2.  Schematic  overview  of  the  growth  parameters  of A. muciniphila. The  optimum  growth 
temperature and pH are 37 °C and 6.5, respectively. In addition, A. muciniphila is able to tolerate nM 
concentrations of oxygen and is able to grow in the presence of 0.1% purified bile salts. 
The  growth  parameters  of A. muciniphila  described  above  coincide with  the  environmental 
parameters  found  in  the  large  intestine. The oxygen concentration  in  the  intestine  follows a steep 
gradient from the intestinal submucosa to the lumen, where the oxygen concentrations decrease to 
near anoxia [52]. A. muciniphila may take advantage of this oxygen concentration in the mucus layer, 
enhancing  its growth. The mucosal  layer of  the  large  intestines  serves as a carbon, nitrogen, and 
energy source for the use of A. muciniphila. The mucin backbone is rich in threonine (among other 
amino acids) and contains many sugar groups, including GlcNAc and GalNAc [53]. As mentioned 















Figure 2. Schematic overview of the growth parameters of A. muciniphila. The optimum growth
temperature and pH are 37 ◦C and 6.5, respectively. In addition, A. muciniphila is able to tolerate nM
concentrations of oxygen and is able to grow in the presence of 0.1% purified bile salts.
The growth parameters of A. muciniphila described above coincide with the environmental
parameters found in the large intestine. The oxygen concentration in the intestine follows a steep
gradient from the intestinal submucosa to the lumen, where the oxygen concentrations decrease to
near anoxia [52]. A. muciniphila may take advantage of this oxygen concentration in the mucus layer,
enhancing its growth. The mucosal layer of the large intestines serves as a carbon, nitrogen, and energy
source for the use of A. muciniphila. The mucin backbo e is rich in threonine (among other amino
acids) and contains many sugar groups, including G cNAc and GalNAc [53]. As mention d earlier,
these are among the minimal growth requirements of A. muciniphila. Although the mucus layer in
the large intestine is thought to be the optimal niche for A. muciniphila, mucus is also present at other
locations of the GIT. Several conditions may vary in the GIT, such as type of mucin that is secreted, pH,
oxygen concentration, and concentration of bile acids. The ability of A. muciniphila to cope with these
conditions will be discussed below.
4. Akkermansia muciniphila along the Human Gastrointestinal Tract
Akkermansia-like spp. were found to be present in different anatomical regions of the digestive
tract, including the oral cavity, breast milk, pancreas, biliary system, small and large intestines, and
appendix (Figure 1b). Next to the aforeme tioned regions, Akkermansia-like sequences were also
detected in human blood [50,54,55] ever, the p sence of Akkermansia-like sequenc s was only
detected in subjects with diseases as septicemia and cirrhosis. In a mice study, A. muciniphila was
detected in the oral cavity, stomach, small intestine, and large intestine the upon administration of
breast milk and formula milk [56]. However, in this review we will mainly focus on the presence of
Akkermansia-like spp. in the human body.
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4.1. Oral Cavity
The oral cavity is a moist environment with a relatively constant temperature between 34 and
36 ◦C [57]. There are several ecological niches in the oral cavity that mostly have a neutral pH.
The mean pH of the mucosal sites was found to be 6.78 ± 0.04 [58]. Examples of different sites in
the oral cavity are the tongue, soft and hard palates, tooth surfaces, and tonsils [57]. In terms of
temperature and pH, the oral cavity can support the growth of a wide variety of microorganisms.
Therefore, the microbial community of the oral cavity is site-specific and highly diverse [59].
Several studies found a high abundance of the phyla Firmicutes, Proteobacteria, Bacteroidetes,
and Actinobacteria, with Streptococcus (belonging to the phylum Firmicutes) being the most
abundant genus [60,61]. The presence of Verrucomicrobia in the oral cavity is often not
described [60–64]. However, the presence of Akkermansia-like sequences was found in the oral cavity
of a choledocholithiasis patient [65]. The salivary samples were taken by gargling with 20 mL of
sterile saline water. Thus, the microorganisms in these samples originate from multiple niches in the
oral cavity.
The relative abundance of Akkermansia-like spp. in this sample was low, namely 0.02% [65].
In addition, these sequences were only found in one out of six patients included in this study. In terms
of pH and temperature, Akkermansia spp. could be able to survive in the oral cavity [11]. Furthermore,
Gram-negative and obligate anaerobes with proteolytic lifestyles are present in healthy gingival crevice
biofilms [66]. As discussed before, A. muciniphila has a mucin-degrading lifestyle [11]. The mucins
found in the oral cavity are MUC5B, MUC7, MUC19, MUC1, and MUC4 [67]. Of these mucin
structures, MUC5B is the most abundant gel-forming mucin in the oral cavity [68,69]. As A. muciniphila
has mucin-degrading enzymes similar to those found in oral Streptococcus spp., A. muciniphila might be
able to use the mucin structures in the oral cavity as a substrate for growth [70,71]. However, further
research is needed to confirm this hypothesis.
Mucin oligosaccharides are able to bind microbes and in some cases exert functions in
antimicrobial activity or carry antimicrobial proteins [67]. For example, MUC7 and MUC5B both
bind statherin and histatin-1. By binding these molecules, mucins exert a protective function in
the oral cavity. The potential role of Akkermansia spp. in the oral cavity is unknown. However,
one could hypothesize that its capability to stimulate the mucus production of the epithelial cells
enhances their protection e.g., against pathogens. Another possibility could be that Akkermansia spp.
produces compounds in mucin degradation that could be useful for other bacteria in the oral microbial
community. Lastly, Akkermansia spp. might be involved in the modulation of the host response.
Altogether, more studies should be conducted to confirm the presence of Akkermansia spp. and its
function in the oral cavity.
4.2. Pancreas
The pancreas is a complex organ comprised of both exocrine glands (secreting digestive enzymes
into the intestinal lumen) and endocrine glands, called the islets of Langerhans, which secrete hormones
directly into the bloodstream [72]. The pancreas plays a central role in human metabolism, allowing
ingested food to be converted and used as fuel by cells throughout the body. The pancreas may be
affected by devastating diseases, such as pancreatitis, pancreatic adenocarcinoma (PAC), and diabetes
mellitus (DM), which generally results in a wide metabolic imbalance [73]. Nutrient metabolism in
pancreatic cells is not only essential for providing energy for the cell, but also serves as a mechanism
to sense and react to circulating levels of macronutrients. This gives the pancreas a central role in
metabolism regulating the whole-body energy homeostasis. Efficient energy metabolism in pancreatic
endocrine cells of the islets is required to permit the secretion of many hormones, mainly insulin and
glucagon, that regulate glucose and lipid utilization throughout the body. The pancreas is thought
to be devoid of bacteria. However, microbial translocation as a result of disease states has led to
measurements of microbes in pancreatic tissue. Because it is dangerous and impossible to take biopsies
of pancreatic tissue, due to the risk of leakage of pancreatic fluid, pancreatic samples can only be
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obtained via surgery. As such, samples of healthy individuals are not yet reported. Healthy controls
are usually healthy tissue surrounding a pathologic site. Recent research has shown that disruption of
pancreatic metabolism is often a consequence of disruptions in the gut microbiome [74]. Another study
has shown that the pH in the pancreas drops significantly (p-value < 0.05) in patients with painful
chronic pancreatitis (7.02 ± 0.06) compared to healthy individuals (7.25 ± 0.04) [75]. That pH change in
patients with chronic pancreatitis might be one of the reasons why the bacterial barrier in the pancreas
is ruptured and the abundance of bacterial phyla and species is elevated [76].
A. muciniphila plays an important role in the maintenance of the gut barrier function [16]. A few
studies have shown the association of A. muciniphila with the pancreas and its health. A recent study
with patients undergoing pancreatic fluid pancreaticoduodenectomy (PD) revealed that the mean
relative abundances of the Verrucomicrobia phylum and Akkermansia genus, respectively, were 0.0005
and 0.0004 in the pancreas of these patients [77]. The study also highlighted that in the pancreas
tissue of the patients, other commensal bacteria were found to be present. The Proteobacteria phylum
and Klebsiella genus were the most abundant, with mean relative abundances of 0.5410 and 0.2011,
respectively. Faecalibacterium, Bacteroides, and Prevotella were also detected in the pancreas of PD
patients. The presence of other gut microbes in the pancreas apart from Akkermansia may indicate
trophic interactions between them.
Interestingly, it was found that mice treated with pancreatic enzyme replacement therapy (PERT),
had a significant, 58-fold increase of A. muciniphila sequences compared to the control samples (mice
treated with tap water) [78]. Furthermore, it is stated that pancrealipase diminishes pancreatic exocrine
insufficiency-associated symptoms by inducing the colonization of A. muciniphila followed by the
normalization of the intestinal barrier. Therefore, it is hard to speculate on the role of Akkermansia
species and/or A. muciniphila in the pancreas.
The Akkermansia genus is detected in the pancreas, mainly in conditions of pathology.
The significant change of pH of the pancreatic fluid in patients with chronic pancreatitis (7.02 ± 0.06)
might be a reason why Akkermansia was detected in pathological conditions. Thus far, there is not
any evidence showing that the pancreas is colonized by bacteria in healthy individuals or that it is a
bacteria-free organ. In all of the studies that have been described so far, the bacterial colonization of the
pancreas is inextricably linked to the cause of pancreatic disease. The higher abundance of bacteria in
patients with pancreatic diseases could be associated with an overall higher abundance of microbiota
members in these states of disease due to bacterial overgrowth and translocation. Decreased gut
barrier function in both acute and chronic pancreatitis increases bacterial translocation. This bacterial
translocation could have significant impact on the nutrient absorption and therefore on the availability
of nutrients for intestinal microorganisms, and the microbial composition of the gut.
4.3. Bile Ducts and Gallblader
Bile is a complex aqueous solution secreted by the liver [79]. Both gallbladder bile and common
bile duct bile of patients undergoing cholecystectomy were found to have an alkaline pH in the
ranges of 6.8–7.65 and 7.5–8.05, respectively [80]. In most animal/mammal species, bile contains
less than 5% solid contents [79]. The most abundant organic substances in bile are bile salts [81].
The primary bile salts in the mammalian liver are cholic acid and chenodeoxycholic acid (CDCA).
They are produced from cholesterol in the liver and are then excreted into the duodenum [82]. Bile
salts exert several functions. For example, they were found to have a role in antimicrobial defense,
promoting lipid absorption and protein digestion and assimilation [83,84]. Conjugation of these bile
salts occurs at the side chain, where either taurine or glycine is added, leading to the formation of
stronger acids [81]. Intestinal bacteria are able to convert the stronger acids producing secondary bile
acids by deconjugating them. Large amounts of bile salts are secreted into the intestine; however, only
limited amounts are excreted from the human body [85]. More than 95% of the bile salts are reabsorbed
in the ileum and redirected to the liver for recirculation. According to this enterohepatic circulation
mechanism, each bile salt is recirculated approximately 20 times.
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Interestingly, the bile duct was first considered to be generally sterile [86]. However, more recently
several studies have focused on the microbial community present in bile [65,77,87–90]. The phyla
Firmicutes, Fusobacteria, Proteobacteria, Actinobacteria, and Bacteroidetes (among others), have
been identified in bile samples [65,77,88,89]. These phyla are all commonly found in the human GI
tract [91]. Subsequently, the bacteria found in the biliary tract are likely to originate from the human
duodenum [65]. The most common genera in bile samples were found to be Prevotella, Streptococcus,
Veillonella, Fusobacterium, and Haemophilus [89].
To study the function of the biliary microbiota, predictive functional profiles were constructed
using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States
(PICRUSt) [65]. This method revealed that biliary bacteria have significantly enriched pathways,
in comparison to the upper digestive tract microbiota, related to environmental information processing,
cell motility, carbohydrate metabolism, amino acid metabolism, and lipid metabolism. Furthermore,
several studies have focused on the role of the biliary microbiota in the development of diseases
such as gallstone disease and biliary neoplasia in primary sclerosing cholangitis (PSC) [88,89,92,93].
However, to explore the exact role of the microbiota in gallstone formation, more research needs to
be conducted. In addition, PSC was not associated with changes in the microbial community of the
biliary system [89]. However, Streptococcus species were found to be positively correlated to disease
progression and might therefore have a pathogenic role in the progression of PSC.
Although the presence of Verrucomicrobia and/or Akkermansia-like sequences has not been
described in all studies involving the biliary microbiota, they have been found to be present in
a proportion of studies including bile samples [65,77,88,89]. In a study describing the bacterial
community in bile and gallstone samples, Akkermansia-like sequences were detected [88]. The relative
abundance of Akkermansia-like sequences in 12 out of 26 bile samples ranged between 0.03 and
0.4%. In addition, 10 out of 29 gallstone samples contained Akkermansia spp. with a relative
abundance ranging between 0.02% and 0.3%. Akkermansia-like sequences were also detected by
another study in the bile sample of one out of six gallstone patients, revealed using V3-4 Illumina
sequencing [65]. The relative abundance of Akkermansia-like sequences in this sample was low,
namely 0.153%. In addition, the mean relative abundances of Verrucomicrobia and Akkermansia
spp. were determined to be 0.05% and 0.04%, respectively, in bile samples from 50 patients undergoing
pancreaticoduodenectomy [77]. Furthermore, bile samples of subjects with opisthorchiasis (bile
duct infection by Opisthorchis felineus [94]) contained higher amounts of Verrucomicrobia (among
other phyla) than subjects with gallstone disease without infection of O. felineus [93]. The presence
of Verrucomicrobia was not specific to the Akkermansia genus and the exact relative abundance of
Verrucomicrobia was not provided. Even though five phyla including Verrucomicrobia were found to
be more abundant in infected subjects than non-infected subjects, there were no functional differences
between these groups based on analysis using PICRUSt. The studies described in this section were
properly controlled for contaminants.
The pH values of gallbladder bile and common bile duct bile are both within the growth range
of A. muciniphila. However, for Akkermansia spp. to be able to remain in bile, they are expected to
harbor a mechanism for protection against bile. A putative bile acid transporter gene (Amuc_0139) is
annotated in the genome of A. muciniphila, which might function to export bile acids from the cell [48].
This process could reduce the effects of bile acids inside the cells of A. muciniphila. Another possible
mechanism, as identified in Bifidobacterium spp., is the protection of the cell wall against bile acids by
the production of exopolysaccharides [95,96]. However, this mechanism has not been identified for
Akkermansia muciniphila.
Several mucins have been identified in the biliary tract, specifically in the gallbladder. The mucins
that are expressed in the gallbladder are MUC3, MUC5B, MUC5AC, and MUC6 [97–100]. Even
though colonic mucin consists mainly of MUC2, A. muciniphila might be able to use the mucins in the
gallbladder as a substrate. Next to Akkermansia spp. other bacteria with mucin-degrading capacities
in the GI tract have been identified in the biliary system. As such, Streptococcus anginosus [93] and
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bacteria with operational taxonomic unit (OTU) IDs with 99% identity matching that of Bacteroides
vulgatus [88] were found to be present in bile samples. Although the function of Akkermansia spp. in the
biliary system is unknown, it might have a role in the strengthening of the mucosal barrier. In this way,
the mucosal layer may provide increased protection against pathogens. This could explain the increase
of Verrucomicrobia during infection of Opisthorchis felineus, since it might function to strengthen the
mucosal barrier and thereby provide protection during infection.
4.4. Small Intestine
The GIT supplies the human body with energy and essential nutrients [101]. This is achieved by
the conversion and absorption of food components reaching the small intestine. The small intestine
can be divided into three segments: duodenum, jejunum, and ileum [102]. The transit time of the
small intestine was found to be between 30 min and 4.5 h [103]. Once the gastric content enters the
duodenum, it is neutralized by bicarbonate derived from the pancreas, liver, and duodenal mucosa,
causing pH fluctuations [104]. More recent investigations of pH profiles revealed that pH values
increased from 5.9–6.3 in the proximal part of the small intestine (duodenum) [105]. In the distal parts,
pH values were found to increase to pH 7.4–7.8.
The epithelial cells within the small intestine are covered with mucus. In contrast to the mucosal
layer in the stomach and the colon, the mucosal layer in the small intestine is thinner and less
dense [106]. In addition, this layer is not firmly attached to the epithelial surface and forms a soluble
mucus gel [106,107]. The mucus gel layers observed in the duodenum and jejunum are similar
in thickness, although no loose/sloppy mucus was found in the jejunum [106]. In contrast to the
duodenum and jejunum, the mucus layer in the ileum is significantly thicker. The accumulation rates
were similar throughout the different segments of the small intestine.
The fast transit time, in comparison to the large intestine, contributes to limited microbial growth
in the small intestine [102]. In addition, the secretion of digestive enzymes and bile into the small
intestine creates a harsh environment in terms of microbial growth [101]. The bacterial concentration
in the duodenum and jejunum is only 103–104 bacteria/mL content [108]. This concentration increases
in the ileum, where the bacterial concentration is 108 bacteria/mL content. Due to the challenging
conditions for microbial growth in the small intestine (acidity and higher oxygen levels than in the
colon), the microbial community is dominated by bacteria that are facultative anaerobic, able to grow
quickly, and able to tolerate bile acids and antimicrobials [109]. At the same time, these bacteria
are also competing with the host and other microorganisms for simple sugars in the small intestine.
Interestingly, phagocytes in the small intestine are thought to play a role in immune surveillance of
the small intestinal mucosa [110]. This means that phagocytes are able to selectively take up bacteria,
which might be linked to maintaining immune homeostasis.
The location of the small intestine in the human body causes difficulties in sampling, in
comparison to, for example, the oral and fecal microbiota. Therefore, fewer studies have been
performed describing the microbiota in the small intestine [101,111]. In the duodenum, the phyla
Firmicutes and Actinobacteria were found to be predominant in the duodenal fluid of both obese and
healthy groups (n = 5 for each group) [112]. Other (less abundant) phyla detected in the duodenum
were Proteobacteria, Fusobacteria, TM7, Bacteroidetes, and Tenericutes. However, an inter-individual
variability in the taxonomic composition between these samples was observed. Even though the
duodenum was found to have fewer OTUs than mouth, colon, and stool samples, it does harbor
most phyla observed in the other sites [91]. The mucosa-associated microbiota of the duodenum was
found to be dominated by the phylum Firmicutes and genus Streptococcus [113]. The genera Prevotella,
Veillonella, and Neisseria were also found to be present in the mucosal layer. Interestingly, the duodenal
mucosa-associated microbiota found in this study overlaps in broader levels of classification with that
of the oral cavity and saliva. Further down the small intestine, the most dominant phyla in jejunal fluid
were found to be Firmicutes, Proteobacteria, and Bacteroidetes [111]. Less abundant phyla (5–10%)
were Actinobacteria and Fusobacteria. In comparison to the findings of the microbiota composition in
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the duodenum, the abundance of Proteobacteria and Bacteroidetes were found to be dominant over
Actinobacteria in the jejunum [111]. When comparing the microbiota composition found in samples
obtained after the washing procedure and mucosal biopsies, these compositions were highly similar.
The last part of the small intestine (ileum) was found to be dominated by the phyla Bacteroidetes,
Clostridium cluster XIVa, and Proteobacteria [101,114].
Several studies have focused on the small intestinal microbiota in disease states, such as IBS,
Crohn’s disease, and liver cirrhosis [115–119]. A study focused on IBS showed that the small intestinal
microbiota of IBS patients and healthy individuals did not differ in terms of major phyla or genera [117].
In contrast, the duodenal mucosal microbiota of cirrhotic patients were surprisingly different to that
of healthy controls [118]. The dysbiosis observed in duodenal samples of cirrhotic patients might be
associated with an altered oral microbiota or an altered environment of the duodenum.
Even though the phylum Verrucomicrobia is not included in the dominant microbial compositions
described above, Verrucomicrobia and Akkermansia-like spp. have been detected in all segments of the
small intestinal tract. In duodenal fluid, Verrucomicrobia and Akkermansia-like spp. were found in
three out of six subjects (with relative abundances of 0.17%, 0.012%, and 0.013%) using V3-4 Illumina
sequencing [65]. In addition, Verrucomicrobia (not specified to Akkermansia) were detected in duodenal
biopsies (0.0688%) and mucus (0.0387%) using 454/Roche GS FLX sequencing [120]. Jejunal contents
have also been shown to harbor Akkermansia-like spp., with a mean relative abundance of 0.01%
(n = 17) [77]. Analysis of swabs from jejunal contents were performed using Illumina MiSeq. Another
study detected Akkermansia-like spp. in four out of 20 subjects with concentrations ranging from
three to 90 hits, equaling to 0 to 0.029% of total hits, also using Illumina MiSeq [77]. Furthermore,
Verrucomicrobia were found in the distal ileum using direct cloning and sequencing, making up 5%
of the detected microbial community [121]. Lastly, Akkermansia-like sequences were detected in the
ileocecal biopsies of patients with PSC and ulcerative colitis, as well as non-inflammatory controls
(relative abundances of 0.49% ± 0.52%, 0.37% ± 0.37%, and 0.36% ± 0.31%, respectively) [122]. In the
schematic tree in Figure 1a, the A. muciniphila sequences derived from ileum biopsies are clustered
together. This occurs in particular in the third clade, which is made up entirely of Akkermansia-like
sequences derived from the ileum, with a 16S rRNA sequence identity of 98% in comparison to
A. muciniphila MucT. The isolation of Akkermansia-like species in the ileum is needed to study possible
differences between the strains found in the small intestine and the strains in the large intestine.
Considering the pH in the small intestine, the Akkermansia-like spp. found in the ileum and other parts
of the small intestine could have a different optimum pH for growth.
The function of the small intestinal microbiota was also studied using comparative metagenomics
and RNAseq [101]. This study, in which A. muciniphila was not detected, revealed that the metabolic
focus small intestinal microbiota lies within carbohydrate uptake and metabolism. In more detail,
simple carbohydrate transport phosphotransferase systems, fermentation, central metabolism, the
metabolism of amino acids, and the production of cofactors were enriched. A more recent study
emphasized that the ileum mucosal microbiota might have a role in plant cell wall polysaccharide
(PCW) degradation [123]. A large portion of the glycans that reach the small intestine are PCW
polysaccharides. These polysaccharides cannot be degraded by humans, whereas the ileal microbiota
associated with the mucus layer was found to have the enzymatic potential to break down PCW
polysaccharides. The exact role of A. muciniphila in the small intestine remains unknown, but
Akkermansia-like spp. could have a role in immune signaling in this part of the GIT. In mice, the
addition of A. muciniphila in comparison with germ-free mice resulted in more significant modulation
in the ileum of PPARα-RXRα activation, tryptophan metabolism, serotonin receptor signaling, and
dopamine receptor signaling, among others [20]. The number of differentially expressed genes in
the ileum of A. muciniphila mono-associated mice was 253 (144 upregulated and 99 downregulated
genes). The administration of A. muciniphila resulted in an increase of Reg3g expression under the
control diet and a decrease of Lyz1 expression in the ileum [10]. Another study also showed a
decrease in Cnr1 expression and increase of Cldn3 expression in the ileum upon the administration of
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A. muciniphila in mice [124]. As discussed before, the mucus layer in the small intestine is thinner and
less dense than that of the colon [106]. This allows closer contact between the microbial community
and host cells, promoting immune signaling in this region of the gastrointestinal tract. The presence of
Akkermansia-like spp. in the ileum might contribute to immune health.
4.5. Large Intestine
The large intestine specializes in digestion and consists of several different segments, namely
the cecum, ascending colon, transverse colon, descending colon, rectum, and anus [125]. The colonic
transit time of healthy individuals is longer than the transit time of the small intestine, ranging between
9 and 46 h (mean 28 h) [126]. In healthy individuals, a decrease in luminal pH is observed in the cecum
in almost all subjects (pH ranging from 5.5–7.5) [127]. This drop in pH is due to the fermentation of
carbohydrates by colonic bacteria, leading to the production of SCFAs. Then, the pH increases along
the large intestines to pH values ranging between 6.1 and 7.5. The mucosal pH of the large intestine
parallels the luminal pH [128]. However, the mucosal pH is less acidic than the luminal pH in all
anatomic regions of the large intestine.
The epithelial cells along the large intestine are covered by the mucosal layer [129]. As such, the
mucosal layer protects the epithelial cells from direct contact with microorganisms. On top of this, the
mucosal layer also contains antimicrobial proteins such as IgA. The mucosal layer can be divided into
two parts: the inner and outer mucus layers. The inner mucus layer is firmly attached to the epithelial
cells and devoid of bacteria, whereas microbes are capable of colonizing the outer layer due to its higher
permeability [107]. Both layers are mainly composed of the gel-forming mucin MUC2, consisting
of large polymers that are formed by N-terminal trimerization and C-terminal dimerization [130].
The expansion of the mucus layer occurs due to increased pH and decreased calcium (Ca2+) levels.
N-terminal interactions are weakened by the decreased calcium concentrations. Therefore, water is
able to bind to the mucin domain glycans, leading to the formation of flat mucin sheets. Furthermore,
the less dense outer layer is the result of endogenous proteases, promoting the possibility of microbes
to colonize the mucus layer [107]. The degradation of these mucins by mucin-degrading bacteria of
the colon microbiota affects the host cells e.g., by producing SCFAs [131].
The gut microbiota is mainly studied using fecal samples, since these samples can be obtained
without colonoscopies. However, microbial communities detected in fecal samples mainly reflect the
luminal microbiota in the distal large intestine. Therefore, the microbial communities in biopsies can
differ distinctly from that in fecal samples [91]. Several studies have confirmed that the microbial
communities in biopsy samples of different anatomic regions of the colon show similarities, focusing
on the major phylogenetic groups [91,121,132]. Along the intestinal tract, Firmicutes and Bacteroidetes
were predominant, with lower proportions of Proteobacteria and Fusobacteria observed in biopsy
samples [91,132]. The sequencing of fecal samples of 22 individuals from four different European
countries revealed the presence of three robust clusters, called enterotypes [133]. These enterotypes
are either enriched in (1) Bacteroides; (2) Prevotella and co-occurring Desulvibrio; or (3) Ruminococcus
and co-occurring Akkermansia. Recently, a method of restricting enterotyping space was proposed to
increase the ability to detect samples outside of these enterotyping spaces [134]. Overall, the dominant
phyla in fecal samples derived from healthy individuals were found to be Firmicutes, Bacteroidetes,
and Actinobacteria. Less abundant phyla were Proteobacteria and Verrucomicrobia [133].
In addition to studies on the role of the gut microbiota in health, the gut microbiota has also been
studied in diseases such as IBD, IBS, obesity, and type-2 diabetes. A shift in microbiota composition
was observed in IBD patients and may have a role in the onset, maintenance, and severity of the disease,
although this shift could also partly be due to the disturbed gut environment [135]. In IBS patients, a
decrease in bacterial diversity was observed [136,137]. However, a consistent gut microbiota pattern
in IBS patients is lacking [138]. In obesity, inconsistent findings have been reported. For example,
one study reported an increase of Firmicutes and a decrease of Bacteroidetes, while another reported
the opposite [139,140]. Lastly, a decrease in canonical butyrate-producing bacteria was found in
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patients with T2D [141]. A decrease in butyrate-producing bacteria was associated with an increase in
opportunistic pathogens, mainly Proteobacteria. Taken together, the studies on the gut microbiota in
individual diseases are not all uniform, highlighting the difficulties in appointing markers for disease.
The gut microbiota plays an important role in the metabolism of host nutrients and the health
maintenance of the host. Carbohydrates (mainly polysaccharides) that have not been hydrolyzed in the
small intestine become available for the microbial community in the colon [142]. The main substrates
entering the colon are resistant starch and polysaccharides derived from plant cell walls. The major
end products produced by the gut microbiota are SCFAs (e.g., acetate, propionate, and butyrate) and
gases (e.g., H2 and CO2) using the available substrates. Of these, butyrate is used as an energy source
by colonic epithelial cells [143]. Furthermore, propionate is able to signal to the host through the
GPR41 and GPR43 receptors [144]. Interestingly, SCFAs activate free fatty acid (FFA) receptor 2 and
FFA3 in the gut [144–146]. These receptors control peptides (peptide YY and glucagon-like peptide 1)
involved in appetite regulation [147]. Therefore, SCFA production in the gut may be associated with
food intake. Next to dietary carbohydrates, the colonic microbiota also has a role in the degradation
of host-derived glycans (mucin), xenobiotics, and drugs [142,148]. The gut microbiota is also able to
stimulate host immunity in order to protect the host against pathogens [149]. In this way, the gut
microbiota enhances the innate immune response and has a role in increasing the gut barrier function.
One of the microbial species in the gut involved in immune regulation and increasing gut barrier
function is A. muciniphila [10,26].
A recent study revealed the presence of Verrucomicrobiae in all anatomical regions of the
large intestine by sequencing the V2 region [34]. The concentrations of Verrucomicrobiae (in
two individuals) ranged between 0.3% and 15.8%. Interestingly, one individual harbored only
low concentrations, ranging between 0.3% and 1.4%, while concentrations in another individual
ranged between 9.8% and 15.8% throughout the anatomic regions. Notably, the individual with
higher Verrucomicrobiae concentrations was a Crohn’s disease patient. Differences were not only
observed between individuals, but also between the experimental designs. The use of another
DNA extraction method resulted in lower amounts of Verrucomicrobiae with concentrations in
the range of 0.3–7.3% in both individuals. Next to this study, there are more studies identifying
the Verrucomicrobia phylum and/or Akkermansia-like spp. focusing on several anatomic regions of
the large intestine [91,121,150–153]. Verrucomicrobia were identified in the cecum by another study,
although quantities were not shown [150]. Even though the pH is lower in the cecum (pH 5.5–7.5),
it is still within the growth range of A. muciniphila. In the ascending colon, Verrucomicrobia were
identified with a concentration of 6% in the large intestine of a healthy volunteer [121]. Using a qPCR
approach within the same region, a concentration of 4.17 ± 0.6 log 10 genomes per gram of a sample
of Akkermansia-like spp. was described [151]. Furthermore, the transverse colon of two out of four
included subjects showed the presence of Verrucomicrobia, with 563 and 7771 sequence counts of
this phylum in each sample [91]. In the sigmoid colon, compared to the transverse colon, the same
study reported a decrease in one of the subjects (from 563 to 64 sequence counts), whereas an increase
was noted in another subject (from 7771 to 11,941 sequence counts). The qPCR approach resulted in a
similar concentration to that found in the ascending colon, namely 4.16 ± 0.56 log 10 genomes per
gram of a sample [151]. Several studies have also described the presence of Akkermansia-like sequences
in the rectum [91,121,152]. Where one study reported a higher concentration in the rectum (9%) than
in the ascending colon, another reported a rapid decrease in sequence counts from 64 and 11,941 in
the sigmoid colon, to sequence counts of 1 and 2, respectively [91,121]. In conclusion, based on these
studies, the presence and abundance of A. muciniphila in the large intestine is subject-specific.
To compare the 16S rRNA Akkermansia-like sequences in biopsies to fecal samples, a maximum
likelihood tree was constructed (Figure S3). Interestingly, the majority of the Akkermansia-like sequences
derived from biopsies were clustered together. This cluster contains a low amount of Akkermansia-like
sequences derived from fecal samples. Therefore, one could hypothesize that sub-populations of
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Akkermansia spp. exist within the large intestine. However, it should be noted that complete Akkermansia
spp. genomes derived from biopsies and lumen are needed to support this hypothesis.
In contrast to the presence of A. muciniphila in other regions of the GIT, its function has been more
explored in its ecological niche. A. muciniphila was found to be correlated to health and inversely
correlated to several disease states (as explained in the introduction). However, besides its presence
in health and disease, A. muciniphila was also found to be involved in syntrophic interactions [154].
For example, co-cultivations of A. muciniphila with butyrate-producing bacteria (Anaerostipes caccae,
Eubacterium hallii, and Faecalibacterium prausnitzii) resulted in butyrate production. Therefore, it is
suggested that the mucus-degrading capacity of A. muciniphila stimulates intestinal metabolite pool
and specifically butyrate levels, which is beneficial for the host. Another example is the release of
sulfate during mucin degradation. This sulfate might be used by sulfate-reducing bacteria in the colon,
producing hydrogen sulfide [155,156]. In turn, A. muciniphila predictively harbors genes involved in
L-cysteine biosynthesis using hydrogen sulfide, suggesting that A. muciniphila might have a role in the
detoxification of hydrogen sulfide in the intestines [157].
As mentioned earlier, the colonization of A. muciniphila in mice led to an increased expression of
genes associated with immune responses and the strengthening of the gut barrier function [10,20]. In
addition, the outer membrane protein (Amuc_1100) was found to be involved in immune regulation
and the enhancement of trans-epithelial resistance [26]. Altogether, these studies suggest an important
role of A. muciniphila in the microbial community of the large intestine in addition to its role in host
interactions, promoting the use of this bacterium as a therapeutic agent for intestinal disorders.
4.6. Appendix
The human appendix extends from the cecum and is 5–10 cm long and 0.5–1 cm wide [158].
The function of the appendix has been up for debate for quite some time. Charles Darwin described the
lack of function of the appendix and noted that the appendix is a remainder from primate ancestors that
ingested leaves, in which the appendix functioned to ferment plant material [159,160]. The appendix
is covered in gut-associated lymphoid tissue, suggesting its involvement in immune function [161].
An apparent function of the human appendix was described, suggesting that the appendix functions as
a “safe house” for beneficial bacteria [158]. This same study revealed a higher abundance of microbial
biofilms in the appendix than other areas of the human colon. To our knowledge, a description of
the pH in the human appendix is lacking. However, the rabbit appendix was found to have a pH
ranging between 6.2 and 6.7 [162]. Secretions of the rabbit appendix are rich in bicarbonate and occur
spontaneously and at a relatively rapid rate (1–12 mL/h). Therefore, it has been suggested that in
rabbits, the appendix may have a major role in the regulation of pH in the cecum. However, similar
data is not available for the human appendix.
Considering the difficulty of obtaining samples of the human appendix, there are few studies
describing the microbiota of the appendix. These studies mainly focus on the microbiota in
appendicitis in comparison to healthy controls [163–165]. In healthy controls, the taxa Fusibacter,
Selenomonas, and Peptostreptococcus were increased in comparison to the rectal microbiota [164].
This finding indicates that the human appendix harbors a distinct microbiota. A wide variation
of abundances in phylum, genus, and species levels was detected within groups divided by
health and severity of inflammation [165]. In healthy controls, Firmicutes and Bacteroidetes
were found to be the most abundant phyla. Other abundant phyla detected in these samples
were Fusobacteria, Actinobacteria, and Proteobacteria. Phyla with lesser abundances (<2%) were
Spirochaetes, Cyanobacteria, Synergistetes, Tenericutes, and Verrucomicrobia.
While some studies found significant differences between the microbiota of appendicitis patients
and healthy controls [163,164] or between severity of inflammation [166], another did not [165].
One of the genera linked to appendicitis is Fusobacterium [163,166]. Increased abundances of this
genus were observed in appendicitis patients in comparison to healthy controls [163], and the
presence of Fusobacterium could be linked to the severity of inflammation [166]. In contrast, the
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presence of A. muciniphila was found to be inversely correlated to the severity of appendicitis [14].
Using fluorescence in situ hybridization (FISH), the mean proportion of single bacterial groups for
A. muciniphila was found to be 4.0 ± 4.6, 1.0 ± 2.1, and 0.2 ± −0.6 for no appendicitis, catarrhal
appendicitis, and suppurative appendicitis, respectively.
The mucus layer of the appendix was found to contain a more concentrated biofilm than other
parts of the large bowel [158]. Therefore, the appendix might be a favorable niche for mucin-degrading
bacteria, including A. muciniphila. Although the role of A. muciniphila in the appendix is not specified,
one could hypothesize that, being part of the appendiceal microbiota, A. muciniphila might have a
role in re-colonizing the colon after an infection or colonic dysfunction. Thereby, A. muciniphila could
function in the maintenance of a healthy gut microbiota by restoring the mucus barrier function
subsequent to infection/inflammation.
4.7. Human Breast Milk and Early Life Intestine
In breast-fed infants, the main source of glycans are human milk oligosaccharides (HMOs) [167].
Human milk consists of a mixture of nutrients for infants, conveying immunologic and other health
benefits [147]. Human milk contains 5–15 g/L HMOs, and over 200 different HMO structures exist.
The major monosaccharides present in HMOs are D-glucose, D-galactose, N-acetyl-glucosamine,
L-fucose, and N-acetylneuraminic acid (sialic acid) [168]. HMOs in the infant gut act as substrates
for specific bacteria in the gastrointestinal tract, functioning as natural prebiotics by stimulating the
growth of beneficial intestinal bacteria such as bifidobacteria and lactobacilli [168,169]. It is remarkable
to mention that milk oligosaccharides and glycoconjugates are able to prevent the development of
pathogens and toxins, inhibiting their binding on the surface of the epithelial cells [170]. The structure
of HMOs has chemical similarities to mucus glycans [171].
A. muciniphila has been identified in human milk samples immediately after delivery (colostrum),
and at 1 and 6 months [172]. A. muciniphila cell counts in breast milk were measured after conducting
qPCR, revealing that A. muciniphila was higher in abundance in overweight than normal weight
mothers, with mean concentrations of 1.25, 1.09, and 1.20 log number of gene copies/mL in colostrum
samples and breast milk samples. Furthermore, A. muciniphila was observed to be present in colostrum
samples that were collected from 11 women after elective caesarean with a median counts number of
0.9 (interquartile range from 0.0 to 1.5) analyzed by qPCR [173]. In turn, in samples from human breast
tissue from 43 women (aged 18 to 90 years), the presence of Akkermansia-like species was found using
16S rRNA sequencing [174].
As mentioned earlier, A. muciniphila is also present in infants’ intestines from the first months of
life [27,29,30]. The structures in HMOs can also be found in mucus glycans [175,176]. A. muciniphila was
able to break down structures of HMOs into simpler sugars, releasing SCFAs (acetate and propionate)
in the media. A. muciniphila expressed enzymes that were involved in carbohydrate and glycan
degradation, such as α-L-fucosidases, exo-α-sialidases, β-galactosidases, and β-hexosaminidases [177].
This indicates that A. muciniphila might be able to use HMOs, using human milk as a sole energy,
carbon, and nitrogen source, which could also explain its presence in breast milk and the breast tissue
of lactating woman.
To confirm this, further research should be conducted to gain more insight in the mucolytic
activities and the function of A. muciniphila in human milk. The presence of Akkermansia spp.
and A. muciniphila specific in human milk may benefit the maturation of the infant’s microbiota
establishment and immune maturation, as its outer protein was found to be involved in immune
regulation [26]. Last but not least, A. muciniphila glycan degradation ability might be proved to play an
important role in the initial colonization of the infant’s gut, thus having a major impact on later life.
4.8. Akkermansia Muciniphila in In Vitro Gut Models
In contrast to invasive sampling of the human body, in vitro models have also been introduced to
study the spatial organization of the human gut microbiota. Multiple in vitro models are available
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for this purpose, such as the Gastro-Intestinal Model (TIM-1 and TIM-2) and the Simulator of
Human Intestinal Microbial Ecosystem (SHIME). The small intestinal model TIM-1 consists of four
compartments representing the stomach, duodenum, jejunum, and ileum [178], while TIM-2 simulates
the large intestine [179]. The SHIME was developed in 1993 [180]. This model simulates five
compartments of the digestive tract, namely the stomach, small intestine, and the ascending, transverse,
and descending colon. In addition, a variation on SHIME was developed, named the mucosal SHIME
(M-SHIME) [181]. The M-SHIME has a mucosal compartment, developed to study the microbial
colonization of the mucus layer.
Most of the studies including A. muciniphila used the SHIME model. The presence of A. muciniphila
in different compartments of in vitro models has also been evaluated [182,183]. In SHIME, Akkermansia
spp. are more abundantly present in the transverse and descending colon compartments than in the
proximal compartments (ascending colon) of this model [182–185]. This is not in concordance with
findings using biopsy samples, where no clear depletion of Verrucomicrobiae was observed in the
ascending colon [34]. Another SHIME experiment also described the distal location of Akkermansia
spp. [184]. In addition, in this model the growth of Akkermansia-like spp. was stimulated by black tea
and red wine grape extract. Interestingly, in M-SHIME, A. muciniphila did not reach high densities as
was observed in the distal compartments in the SHIME setup [186]. This might be due to the setup
of the M-SHIME model, which is lacking distal colon compartments, where Akkermansia-like spp.
reached the highest densities [182,184,185]. Recently, a study using the SHIME model demonstrated
that A. muciniphila is pH- and mucin-dependent [183]. An increase of A. muciniphila was observed
upon the addition of mucin. When the pH in the distal colon was lowered, a decrease in A. muciniphila
was observed in comparison to the same compartment with a higher pH. Altogether, these studies
suggest that these models can be used to study the effect of environmental parameters and diet on the
human gut microbiota in health and disease states.
5. Conclusions
To date, the presence of A. muciniphila has mainly been associated with the mucus layer of the
colon. However, in this review we collected results from other studies and showed that Akkermansia-like
sequences have also been found to be present in other anatomical regions of the digestive tract and
human breast milk. In short, these regions are the oral cavity, pancreas, bile ducts and gallbladder,
small intestine, large intestine, and appendix (Figure 1b). The environmental parameters (e.g., pH,
oxygen and nutrient availability) differ among anatomic regions of the human body, affecting the
growth of A. muciniphila. As the aforementioned organs have different functions, the function of
A. muciniphila might also differ in different regions of the digestive tract. In this review, we proposed
hypothetical functions of A. muciniphila in these regions; however, further research is needed to confirm
its role among the different regions of the digestive tract. Altogether, the presence of Akkermansia-like
spp. along the digestive tract indicates that this bacterium might have more functions than those
known so far. Still, as can be concluded from abundance of Akkermansia-like spp., its optimal ecological
niche remains the mucus layer in the colon.
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